Neuroradiology: from Imaging to Therapy
Quick, effective diagnosis can mean the difference between full recovery and possible permanent disability. That’s why Siemens offers the most comprehensive range of Neuroradiology products and services to help you achieve high clinical confidence, offer reliable imaging services, and rapidly share vital information.
Siemens CT Neuro Engine and SOMATOM CT scanner technology offer a unique and complete solution for all aspects of Neuroradiology, allowing high workflow efficiency and offering the potential for better quality patient care.
Siemens is the first company to announce a comprehensive imaging solution by combining reliable radiopharmaceutical manufacturing and distribution with innovative PET hardware and software1 for PET imaging of amyloid plaques—one of the necessary pathological features of Alzheimer’s disease2,3,4 — in the living brain.
Highly detailed images of fine cerebral vessels, aneurysms, tumor anatomy, AVMs and stent deployments in the interventional suite can be obtained with the Artis zee systems and syngo DynaCT.
Speed, non-invasiveness, sensitivity, and specificity with respect to disease characterization are the major advantages of MRI in neuroradiology. Our Biograph mMR and MAGNETOM systems provide unmatched performance in diagnosis of tumors, brain degenerative diseases, and stroke and trauma.
University of Utah: Time vs. Tissue
Is time still the most important factor in stroke diagnosis?
University of Utah Hospital
Stroke assessment in less time with low dose
Norton Brownsboro Healthcare: Siemens
Pregnant with twins and brain AVM
Learn how Siemens SOMATOM Definition™ Flash and SOMATOM Definition™ AS have the coverage that meets your clinical needs.
1syngo.PET Amyloid Plaque is intended for use only with approved amyloid radiopharmaceuticals in the country of use. Users should review the drug labeling for approved uses.
2Hyman BT, Phelps CH, Beach TG, et al. National Institute on Aging–Alzheimer’s Association Guidelines for the Neuropathologic Assessment of Alzheimer’s Disease. Alzheimers Dement. 2012;8:1-13.
3Mirra SS, Heyman A, McKeel D, et al; and participating CERAD neuropathologists. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD): Part II: Standardization of the Neuropathologic Assessment of Alzheimer’s Disease. Neurology. 1991;41(4):479–486.
4Thies W, Bleiler L; Alzheimer’s Association. Alzheimer’s Association Report: 2012 Alzheimer’s Disease Facts and Figures. Alzheimers Dement. 2012;8:131-168